-
Company Profile
Exact Sciences Corp – Company Profile
Exact Sciences Corp (Exact Sciences) is a molecular diagnostic company that focuses on the development of tests for various types of cancers. The company’s flagship product, Cologuard test is a US FDA-approved non-invasive stool-based deoxyribonucleic acid (DNA) screening product indicated for the early detection of colorectal cancer and pre-cancer. It uses a multi-target approach to detect DNA and hemoglobin biomarkers is related to colorectal cancer. The company also offers Oncotype DX gene expression tests for prostate, breast, and colon cancers;...
Add to Basket -
Product Insights
NewExact Sciences Corp Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Exact Sciences Corp Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Exact Sciences Corp (Exact Sciences) is a molecular diagnostic company that focuses on the development of tests for various types of cancers. The company’s flagship product, Cologuard test is a US FDA-approved non-invasive stool-based deoxyribonucleic acid (DNA) screening product indicated for the early detection of colorectal cancer and pre-cancer. It uses a multi-target approach to detect DNA and hemoglobin...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – niclosamide
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry niclosamide Drug Details Niclosamide is under development for the treatment of metastatic hormone-refractory (castration-resistant,...
-
Product Insights
Prostate Cancer Diagnostic Tests – Medical Devices Pipeline Assessment, 2020
Prostate Cancer Diagnostic Tests include assays of mostly antibodies released in response to a prostate cancer and cancer-causing proteins. GlobalData's Medical Devices sector report, “Prostate Cancer Diagnostic Tests-Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Prostate Cancer Diagnostic Tests pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. The Prostate Cancer Diagnostic Tests Pipeline Assessment report provides key information and data related to: Extensive...